Vimarsana
Biggest News Aggregation in the World

Page 7 - Sci Communications News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Sci Communications. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Sci Communications Today - Breaking & Trending Today

9 Meters Biopharma to Exhibit at Digestive Disease Week 2022 - Vimarsana News

9 Meters Biopharma to Exhibit at Digestive Disease Week 2022

RALEIGH, NC / ACCESSWIRE / May 19, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced

9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium - Vimarsana News

9 Meters Biopharma to Present at the H.C. Wainwright Global Investment Conference and the LifeSci Partners Immunology & Inflammation Symposium

RALEIGH, NC / ACCESSWIRE / May 5, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive diseases, announced

9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease - Vimarsana News

9 Meters Biopharma and Celiac.com Announce Collaboration to Support Clinical Trial Enrollment in 9 Meter's Phase 3 Study for Celiac Disease

RALEIGH, NC and SANTA ROSA, CA / ACCESSWIRE / April 20, 2022 / 9 Meters Biopharma, Inc. (NASDAQ:NMTR), a clinical-stage company pioneering novel treatments for people with rare or debilitating digestive

Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022 - Vimarsana News

Omega Therapeutics Presents Preclinical Data on OTX-2002, First-in-Class Epigenomic Controller, as Potential Treatment for Hepatocellular Carcinoma at the AACR Annual Meeting 2022

/PRNewswire/ -- Omega Therapeutics (NASDAQ: OMGA) (Omega), a development-stage biotechnology company pioneering the first systematic approach to use mRNA...

Selecta Biosciences Announces $38.7 Million Underwritten - Vimarsana News

Selecta Biosciences Announces $38.7 Million Underwritten

WATERTOWN, Mass., April 06, 2022 (GLOBE NEWSWIRE) -- Selecta Biosciences, Inc. (Nasdaq: SELB) (“Selecta” or the “Company”), a biotechnology company...